Inhibition of Ovarian Cancer Growth by Bombesin Antagonists
Author Information
Author(s): Chatzistamou I, Schally A V, Sun B, Armatis P, Szepeshazi K
Primary Institution: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine
Hypothesis
Bombesin-like peptides could function as growth factors in human ovarian cancers, and their antagonists may inhibit tumor growth.
Conclusion
Bombesin/GRP antagonists significantly inhibit the growth of OV-1063 ovarian cancers by downregulating c-jun and c-fos oncogenes.
Supporting Evidence
- Treatment with RC-3940-II decreased tumor volume by 60.9% and 73.5% at different doses.
- RC-3095 reduced the volume of OV-1063 tumors by 47.7%.
- Cetrorelix caused a 64.2% inhibition of tumor growth.
- RC-3940-II inhibited the stimulatory effect of GRP(14–27) on c-jun and c-fos in vitro.
- In vivo, c-jun and c-fos mRNA levels were decreased by 43% and 45% respectively after treatment with RC-3940-II.
Takeaway
This study found that certain drugs can help stop ovarian cancer from growing by blocking signals that tell the cancer to grow.
Methodology
The study involved treating OV-1063 human ovarian carcinoma cells xenografted into nude mice with bombesin antagonists and measuring tumor volume and gene expression.
Participant Demographics
Nude mice were used for the xenograft model.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website